Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Novel Perspective for Antithrombotic Therapy in TAVI

Author(s): Maria Drakopoulou, Stergios Soulaidopoulos, George Oikonomou, Konstantinos Stathogiannis, George Latsios, Andreas Synetos, Dimitrios Tousoulis and Konstantinos Toutouzas*

Volume 26, Issue 23, 2020

Page: [2789 - 2803] Pages: 15

DOI: 10.2174/1381612826666200413083746

Price: $65

Abstract

While surgical aortic valve replacement (SAVR) was for years the only available treatment for symptomatic aortic stenosis, the introduction of transcatheter aortic valve implantation (TAVI) in 2002 and the improvement of its technical aspects in the following years, has holistically changed the synchronous therapeutic approach of aortic valve stenosis. Recent evidence has expanded the indication of TAVI from high to lower surgical risk populations with symptomatic aortic stenosis. The administration of antithrombotic therapy periprocedurally and its maintenance after a successful TAVI is crucial for the prevention of complications and affects postprocedural survival. Randomized controlled trials investigating the appropriate combination and the duration of antithrombotic treatment after TAVI are for the moment scarce. This review article sheds light on the underlying pathogenetic mechanisms contributing in periprocedural TAVI thrombotic complications and discuss the efficacy of current antithrombotic policies as evaluated in randomized trials.

Keywords: TAVI, antithrombotic therapy, DAPT, NOAC, VKA, SAVR.

« Previous
[1]
Baumgartner H. Aortic stenosis: medical and surgical management. Heart 2005; 91(11): 1483-8.
[http://dx.doi.org/10.1136/hrt.2004.056176] [PMID: 16230456]
[2]
Smith CR, Leon MB, Mack MJ, et al. PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364(23): 2187-98.
[http://dx.doi.org/10.1056/NEJMoa1103510] [PMID: 21639811]
[3]
Reardon MJ, Van Mieghem NM, Popma JJ, et al. SURTAVI Investigators. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2017; 376(14): 1321-31.
[http://dx.doi.org/10.1056/NEJMoa1700456] [PMID: 28304219]
[4]
Mack MJ, Leon MB, Thourani VH, et al. PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med 2019; 380(18): 1695-705.
[http://dx.doi.org/10.1056/NEJMoa1814052] [PMID: 30883058]
[5]
Khatri PJ, Webb JG, Rodés-Cabau J, et al. Adverse effects associated with transcatheter aortic valve implantation: a meta-analysis of contemporary studies. Ann Intern Med 2013; 158(1): 35-46.
[http://dx.doi.org/10.7326/0003-4819-158-1-201301010-00007] [PMID: 23277899]
[6]
Davlouros PA, Mplani VC, Koniari I, Tsigkas G, Hahalis G. Transcatheter aortic valve replacement and stroke: a comprehensive review. J Geriatr Cardiol 2018; 15(1): 95-104.
[http://dx.doi.org/10.11909/j.issn.1671-5411.2018.01.008] [PMID: 29434631]
[7]
Vahanian A, Alfieri O, Andreotti F, et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33(19): 2451-96.
[http://dx.doi.org/10.1093/eurheartj/ehs109] [PMID: 22922415]
[8]
Gargiulo G, Collet J-P, Valgimigli M. Antithrombotic therapy in TAVI patients: changing concepts. EuroIntervention 2015; 11(Suppl. W): W92-5.
[http://dx.doi.org/10.4244/EIJV11SWA28] [PMID: 26384206]
[9]
Baumgartner H, Falk V, Bax JJ, et al. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38(36): 2739-91.
[http://dx.doi.org/10.1093/eurheartj/ehx391] [PMID: 28886619]
[10]
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135(25): e1159-95.
[http://dx.doi.org/10.1161/CIR.0000000000000503] [PMID: 28298458]
[11]
Popma JJ, Deeb GM, Yakubov SJ, et al. Evolut Low Risk Trial Investigators. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med 2019; 380(18): 1706-15.
[http://dx.doi.org/10.1056/NEJMoa1816885] [PMID: 30883053]
[12]
Blackman DJ, Saraf S, MacCarthy PA, et al. Long-Term Durability of Transcatheter Aortic Valve Prostheses. J Am Coll Cardiol 2019; 73(5): 537-45.
[http://dx.doi.org/10.1016/j.jacc.2018.10.078] [PMID: 30732706]
[13]
Swinkels BM, Plokker HW. Evaluating operative mortality of cardiac surgery: first define operative mortality. Neth Heart J 2010; 18(7-8): 344-5.
[http://dx.doi.org/10.1007/BF03091788] [PMID: 20729999]
[14]
Roques F, Nashef SA, Michel P, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg 1999; 15(6): 816-22.
[http://dx.doi.org/10.1016/S1010-7940(99)00106-2] [PMID: 10431864]
[15]
Balan P, Zhao Y, Johnson S, et al. The Society of Thoracic Surgery Risk Score as a Predictor of 30-Day Mortality in Transcatheter vs Surgical Aortic Valve Replacement: A Single-Center Experience and its Implications for the Development of a TAVR Risk-Prediction Model. J Invasive Cardiol 2017; 29(3): 109-14.
[PMID: 28255105]
[16]
Reardon MJ, Adams DH, Kleiman NS, et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2015; 66(2): 113-21.
[http://dx.doi.org/10.1016/j.jacc.2015.05.017] [PMID: 26055947]
[17]
Osswald BR, Gegouskov V, Badowski-Zyla D, et al. Overestimation of aortic valve replacement risk by EuroSCORE: implications for percutaneous valve replacement. Eur Heart J 2009; 30(1): 74-80.
[http://dx.doi.org/10.1093/eurheartj/ehn523] [PMID: 19033261]
[18]
Cocchia R, D’Andrea A, Conte M, et al. Patient selection for transcatheter aortic valve replacement: A combined clinical and multimodality imaging approach. World J Cardiol 2017; 9(3): 212-29.
[http://dx.doi.org/10.4330/wjc.v9.i3.212] [PMID: 28400918]
[19]
Li Z, Dawson E, Moodie J, et al. Frailty in patients undergoing transcatheter aortic valve implantation: a protocol for a systematic review. BMJ Open 2019; 9(2), e024163
[http://dx.doi.org/10.1136/bmjopen-2018-024163] [PMID: 30782896]
[20]
Mahmaljy H, Young M. Transcatheter Aortic Valve Replacement (TAVR/TAVI, Percutaneous Replacement). StatPearls Publishing 2019.
[21]
Pilgrim T, Lee JKT, O’Sullivan CJ, et al. Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. Open Heart 2018; 5(1)e000695
[http://dx.doi.org/10.1136/openhrt-2017-000695] [PMID: 29387427]
[22]
Tchetche D, Van Mieghem NM. D. T.New-generation TAVI devices: description and specifications. EuroIntervention 2014; 10(Suppl. U): U90-U100.
[http://dx.doi.org/10.4244/EIJV10SUA13] [PMID: 25256338]
[23]
Leon MB, Smith CR, Mack M, et al. PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363(17): 1597-607.
[http://dx.doi.org/10.1056/NEJMoa1008232] [PMID: 20961243]
[24]
Leon MB, Smith CR, Mack MJ, et al. PARTNER 2 Investigators. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 2016; 374(17): 1609-20.
[http://dx.doi.org/10.1056/NEJMoa1514616] [PMID: 27040324]
[25]
Paul S, Aziz M, Bad Nauheim K-K, et al. Matched Comparison of Self-Expanding Transcatheter Heart Valves for the Treatment of Failed Aortic Surgical Bioprosthesis Insights From the Valve-in-Valve International Data Registry (VIVID). Structural Heart Disease 2017.
[26]
Kandail HS, Trivedi SD, Shaikh AC, et al. Impact of annular and supra-annular CoreValve deployment locations on aortic and coronary artery hemodynamics. J Mech Behav Biomed Mater 2018; 86: 131-42.
[http://dx.doi.org/10.1016/j.jmbbm.2018.06.032] [PMID: 29986288]
[27]
Rashid HN, Nasis A, Gooley RP, Cameron JD, Brown AJ. The prevalence of computed tomography-defined leaflet thrombosis in intra- versus supra-annular transcatheter aortic valve prostheses. Catheter Cardiovasc Interv 2018; 92(7): 1414-6.
[http://dx.doi.org/10.1002/ccd.27702] [PMID: 30218474]
[28]
Rosseel L, De Backer O, Søndergaard L. Clinical valve thrombosis and subclinical leaflet thrombosis in transcatheter aortic heart valves: clinical manifestations, diagnosis, and treatment. Precis Clin Med 2018; 1: 111-7.
[http://dx.doi.org/10.1093/pcmedi/pby016]
[29]
Binder RK, Rodés-Cabau J, Wood DA, Webb JG. Edwards SAPIEN 3 valve. EuroIntervention 2012; 8(Suppl. Q): Q83-7.
[http://dx.doi.org/10.4244/EIJV8SQA15] [PMID: 22995118]
[30]
Manoharan G, Walton AS, Brecker SJ, et al. Treatment of Symptomatic Severe Aortic Stenosis With a Novel Resheathable Supra-Annular Self-Expanding Transcatheter Aortic Valve System. JACC Cardiovasc Interv 2015; 8(10): 1359-67.
[http://dx.doi.org/10.1016/j.jcin.2015.05.015] [PMID: 26315740]
[31]
Barker CM, Reardon MJ. Transcatheter aortic valve replacement with the Lotus valve system. Future Cardiol 2018; 14(5): 367-73.
[http://dx.doi.org/10.2217/fca-2018-0044] [PMID: 30141342]
[32]
Nai Fovino L, Badawy MRA, Fraccaro C, et al. Transfemoral aortic valve implantation with new-generation devices: the repositionable Lotus vs. the balloon-expandable Edwards Sapien 3 valve. J Cardiovasc Med (Hagerstown) 2018; 19(11): 655-63.
[http://dx.doi.org/10.2459/JCM.0000000000000705] [PMID: 30299408]
[33]
Manoharan G, Spence MS, Rodés-Cabau J, Webb JG. St Jude Medical Portico valve. EuroIntervention 2012; 8(Suppl. Q): Q97-Q101.
[http://dx.doi.org/10.4244/EIJV8SQA18] [PMID: 22995122]
[34]
Zembala MO, Piegza J, Wacławski J, et al. Symetis Acurate Transapical Aortic Valve: the initial experience with a second generation of transcatheter aortic valve replacement device. Kardiol Pol 2014; 72(2): 187-93.
[http://dx.doi.org/10.5603/KP.2014.0029] [PMID: 24604504]
[35]
Möllmann H, Hengstenberg C, Hilker M, et al. Real-world experience using the ACURATE neo prosthesis: 30-day outcomes of 1,000 patients enrolled in the SAVI TF registry. EuroIntervention 2018; 13(15): e1764-70.
[http://dx.doi.org/10.4244/EIJ-D-17-00628] [PMID: 29131801]
[36]
Reichenspurner H, Schaefer A, Schäfer U, et al. Self-Expanding Transcatheter Aortic Valve System for Symptomatic High-Risk Patients With Severe Aortic Stenosis. J Am Coll Cardiol 2017; 70(25): 3127-36.
[http://dx.doi.org/10.1016/j.jacc.2017.10.060] [PMID: 29268926]
[37]
Wenaweser P, Stortecky S, Schütz T, et al. Transcatheter aortic valve implantation with the NVT Allegra transcatheter heart valve system: first-in-human experience with a novel self-expanding transcatheter heart valve. EuroIntervention 2016; 12(1): 71-7.
[http://dx.doi.org/10.4244/EIJV12I1A13] [PMID: 27173865]
[38]
Silaschi M, Conradi L, Wendler O, et al. The JUPITER registry: One-year outcomes of transapical aortic valve implantation using a second generation transcatheter heart valve for aortic regurgitation. Catheter Cardiovasc Interv 2018; 91(7): 1345-51.
[http://dx.doi.org/10.1002/ccd.27370] [PMID: 29171730]
[39]
Breyne J, Juthier F, Corseaux D, et al. Atherosclerotic-like process in aortic stenosis: activation of the tissue factor-thrombin pathway and potential role through osteopontin alteration. Atherosclerosis 2010; 213(2): 369-76.
[http://dx.doi.org/10.1016/j.atherosclerosis.2010.07.047] [PMID: 20732681]
[40]
Marechaux S, Corseaux D, Vincentelli A, et al. Identification of tissue factor in experimental aortic valve sclerosis. Cardiovasc Pathol 2009; 18(2): 67-76.
[http://dx.doi.org/10.1016/j.carpath.2007.12.014] [PMID: 18402835]
[41]
Tay ELW, Gurvitch R, Wijesinghe N, et al. A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2011; 4(12): 1290-7.
[http://dx.doi.org/10.1016/j.jcin.2011.08.012] [PMID: 22192370]
[42]
Testa L, Latib A. Assessing the Risk of Leaflet Motion Abnormality Following Transcatheter Aortic Valve Implantation. Interv Cardiol (Lond) 2018; 13(1): 37-9.
[http://dx.doi.org/10.15420/icr.2017:24:2] [PMID: 29593835]
[43]
Chakravarty T, Søndergaard L, Friedman J, et al. RESOLVE SAVORY Investigators. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet 2017; 389(10087): 2383-92.
[http://dx.doi.org/10.1016/S0140-6736(17)30757-2] [PMID: 28330690]
[44]
Latib A, Naganuma T, Abdel-Wahab M, et al. Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv 2015; 8(4)e001779
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.114.001779] [PMID: 25873727]
[45]
Jose J, Sulimov DS, El-Mawardy M, et al. Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics, and Treatment Outcomes. JACC Cardiovasc Interv 2017; 10(7): 686-97.
[http://dx.doi.org/10.1016/j.jcin.2017.01.045] [PMID: 28385406]
[46]
Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 2012; 308(20): 2118-25.
[http://dx.doi.org/10.1001/jama.2012.54506] [PMID: 23188028]
[47]
Gargiulo G, Valgimigli M, Capodanno D, Bittl JA. State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation - past, present and future perspectives. EuroIntervention 2017; 13(6): 717-33.
[http://dx.doi.org/10.4244/EIJ-D-17-00468] [PMID: 28844033]
[48]
Gargiulo G, Windecker S, Vranckx P, Gibson CM, Mehran R, Valgimigli M. A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More? Circulation 2016; 134(23): 1881-906.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.023952] [PMID: 27920074]
[49]
Capodanno D, Gargiulo G, Buccheri S, Giacoppo D, Capranzano P, Tamburino C. Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: Do Bleeding and Stent Thrombosis Weigh Similar on Mortality? J Am Coll Cardiol 2015; 66(14): 1639-40.
[http://dx.doi.org/10.1016/j.jacc.2015.05.085] [PMID: 26429096]
[50]
Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 2017; 38(11): 804-10.
[http://dx.doi.org/10.1093/eurheartj/ehw525] [PMID: 28363222]
[51]
Costa F, van Klaveren D, James S, et al. PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389(10073): 1025-34.
[http://dx.doi.org/10.1016/S0140-6736(17)30397-5] [PMID: 28290994]
[52]
Gargiulo G, Windecker S, da Costa BR, et al. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016; 355: i5483.
[http://dx.doi.org/10.1136/bmj.i5483] [PMID: 27811064]
[53]
Gargiulo G, Ariotti S, Santucci A, et al. Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial. JACC Cardiovasc Interv 2016; 9(17): 1780-9.
[http://dx.doi.org/10.1016/j.jcin.2016.05.046] [PMID: 27544007]
[54]
Gargiulo G, Valgimigli M. Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle. J Thorac Dis 2017; 9(11): 4260-5.
[http://dx.doi.org/10.21037/jtd.2017.10.28] [PMID: 29268486]
[55]
Bagur R. Transcatheter aortic valve looking for low-risk patients: a post hoc analysis of SURTAVI keeps opening the door. EuroIntervention 2018; 14(8): 846-8.
[http://dx.doi.org/10.4244/EIJV14I8A151] [PMID: 30339129]
[56]
Wang J, Yu W, Jin Q, et al. Risk Factors for Post-TAVI Bleeding According to the VARC-2 Bleeding Definition and Effect of the Bleeding on Short-Term Mortality: A Meta-analysis. Can J Cardiol 2017; 33(4): 525-34.
[http://dx.doi.org/10.1016/j.cjca.2016.12.001] [PMID: 28256429]
[57]
Nesbitt WS, Westein E, Tovar-Lopez FJ, et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. Nat Med 2009; 15(6): 665-73.
[http://dx.doi.org/10.1038/nm.1955] [PMID: 19465929]
[58]
Ju L, McFadyen JD, Al-Daher S, et al. Compression force sensing regulates integrin αIIbβ3 adhesive function on diabetic platelets. Nat Commun 2018; 9(1): 1087.
[http://dx.doi.org/10.1038/s41467-018-03430-6] [PMID: 29540687]
[59]
Makki N, Shreenivas S, Kereiakes D, Lilly S. A meta-analysis of reduced leaflet motion for surgical and transcatheter aortic valves: Relationship to cerebrovascular events and valve degeneration. Cardiovasc Revasc Med 2018; 19(7 Pt B): 868-73.
[http://dx.doi.org/10.1016/j.carrev.2018.03.003] [PMID: 29759854]
[60]
Del Trigo M, Muñoz-Garcia AJ, Wijeysundera HC, et al. Incidence, Timing, and Predictors of Valve Hemodynamic Deterioration After Transcatheter Aortic Valve Replacement: Multicenter Registry. J Am Coll Cardiol 2016; 67(6): 644-55.
[http://dx.doi.org/10.1016/j.jacc.2015.10.097] [PMID: 26868689]
[61]
Ruile P, Jander N, Blanke P, et al. Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation. Clin Res Cardiol 2017; 106(2): 85-95.
[http://dx.doi.org/10.1007/s00392-016-1052-3] [PMID: 27853942]
[62]
Ruile P, Minners J, Breitbart P, et al. Medium-Term Follow-Up of Early Leaflet Thrombosis After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv 2018; 11(12): 1164-71.
[http://dx.doi.org/10.1016/j.jcin.2018.04.006] [PMID: 29929639]
[63]
Hafiz AM, Kalra A, Ramadan R, et al. Clinical or Symptomatic Leaflet Thrombosis Following Transcatheter Aortic Valve Replacement: Insights from the U.S. FDA MAUDE Database. Struct Hear 2017; 1: 256-64.
[http://dx.doi.org/10.1080/24748706.2017.1366086]
[64]
Alassar A, Soppa G, Edsell M, et al. Incidence and mechanisms of cerebral ischemia after transcatheter aortic valve implantation compared with surgical aortic valve replacement. Ann Thorac Surg 2015; 99(3): 802-8.
[http://dx.doi.org/10.1016/j.athoracsur.2014.09.054] [PMID: 25586706]
[65]
Miller DC, Blackstone EH, Mack MJ, et al. PARTNER Trial Investigators and Patients PARTNER Stroke Substudy Writing Group and Executive Committee. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg 2012; 143(4): 832-843.e13.
[http://dx.doi.org/10.1016/j.jtcvs.2012.01.055] [PMID: 22424519]
[66]
Kahlert P, Knipp SC, Schlamann M, et al. Silent and apparent cerebral ischemia after percutaneous transfemoral aortic valve implantation: a diffusion-weighted magnetic resonance imaging study. Circulation 2010; 121(7): 870-8.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.855866] [PMID: 20177005]
[67]
Arnold M, Schulz-Heise S, Achenbach S, et al. Embolic cerebral insults after transapical aortic valve implantation detected by magnetic resonance imaging. JACC Cardiovasc Interv 2010; 3(11): 1126-32.
[http://dx.doi.org/10.1016/j.jcin.2010.09.008] [PMID: 21087747]
[68]
Ghanem A, Müller A, Nähle CP, et al. Risk and fate of cerebral embolism after transfemoral aortic valve implantation: a prospective pilot study with diffusion-weighted magnetic resonance imaging. J Am Coll Cardiol 2010; 55(14): 1427-32.
[http://dx.doi.org/10.1016/j.jacc.2009.12.026] [PMID: 20188503]
[69]
Kahlert P, Al-Rashid F, Döttger P, et al. Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler study. Circulation 2012; 126(10): 1245-55.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.092544] [PMID: 22899774]
[70]
Van Mieghem NM, Schipper MEI, Ladich E, et al. Histopathology of embolic debris captured during transcatheter aortic valve replacement. Circulation 2013; 127(22): 2194-201.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.001091] [PMID: 23652860]
[71]
Kapadia SR, Kodali S, Makkar R, et al. SENTINEL Trial Investigators. Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2017; 69(4): 367-77.
[http://dx.doi.org/10.1016/j.jacc.2016.10.023] [PMID: 27815101]
[72]
Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 2012; 33(19): 2403-18.
[http://dx.doi.org/10.1093/eurheartj/ehs255] [PMID: 23026477]
[73]
Van Gils L, Kroon H, Daemen J, et al. Complete filter-based cerebral embolic protection with transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2018; 91(4): 790-7.
[http://dx.doi.org/10.1002/ccd.27323] [PMID: 28895285]
[74]
Schmidt T, Akdag O, Wohlmuth P, et al. Histological Findings and Predictors of Cerebral Debris From Transcatheter Aortic Valve Replacement: The ALSTER Experience. J Am Heart Assoc 2016; 5(11)e004399
[http://dx.doi.org/10.1161/JAHA.116.004399] [PMID: 27930358]
[75]
Schmidt T, Schlüter M, Alessandrini H, et al. Histology of debris captured by a cerebral protection system during transcatheter valve-in-valve implantation. Heart 2016; 102(19): 1573-80.
[http://dx.doi.org/10.1136/heartjnl-2016-309597] [PMID: 27220695]
[76]
Kataoka Y, Puri R, Pisaniello AD, et al. Aortic atheroma burden predicts acute cerebrovascular events after transcatheter aortic valve implantation: insights from volumetric multislice computed tomography analysis. EuroIntervention 2016; 12(6): 783-9.
[http://dx.doi.org/10.4244/EIJV12I6A127] [PMID: 27542792]
[77]
Gargiulo G, Capodanno D, Sannino A, et al. New-onset atrial fibrillation and increased mortality after transcatheter aortic valve implantation: A causal or spurious association? Int J Cardiol 2016; 203: 264-6.
[http://dx.doi.org/10.1016/j.ijcard.2015.10.133] [PMID: 26519681]
[78]
Sannino A, Gargiulo G, Schiattarella GG, et al. A meta-analysis of the impact of pre-existing and new-onset atrial fibrillation on clinical outcomes in patients undergoing transcatheter aortic valve implantation. EuroIntervention 2016; 12(8): e1047-56.
[http://dx.doi.org/10.4244/EIJY15M11_12] [PMID: 26610809]
[79]
Eggebrecht H, Schmermund A, Voigtländer T, Kahlert P, Erbel R, Mehta RH. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention 2012; 8(1): 129-38.
[http://dx.doi.org/10.4244/EIJV8I1A20] [PMID: 22391581]
[80]
Seeger J, Kapadia SR, Kodali S, et al. Rate of peri-procedural stroke observed with cerebral embolic protection during transcatheter aortic valve replacement: a patient-level propensity-matched analysis. Eur Heart J 2019; 40(17): 1334-40.
[http://dx.doi.org/10.1093/eurheartj/ehy847] [PMID: 30590554]
[81]
Lenders GD, Paelinck BP, Wouters K, et al. Transesophageal echocardiography for cardiac thromboembolic risk assessment in patients with severe, symptomatic aortic valve stenosis referred for potential transcatheter aortic valve implantation. Am J Cardiol 2013; 111(10): 1470-4.
[http://dx.doi.org/10.1016/j.amjcard.2013.01.302] [PMID: 23433762]
[82]
Nombela-Franco L, Rodés-Cabau J, DeLarochellière R, et al. Predictive factors, efficacy, and safety of balloon post-dilation after transcatheter aortic valve implantation with a balloon-expandable valve. JACC Cardiovasc Interv 2012; 5(5): 499-512.
[http://dx.doi.org/10.1016/j.jcin.2012.02.010] [PMID: 22625188]
[83]
Nombela-Franco L, Webb JG, de Jaegere PP, et al. Timing, predictive factors, and prognostic value of cerebrovascular events in a large cohort of patients undergoing transcatheter aortic valve implantation. Circulation 2012; 126(25): 3041-53.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.110981] [PMID: 23149669]
[84]
Stortecky S, Windecker S, Pilgrim T, et al. Cerebrovascular accidents complicating transcatheter aortic valve implantation: frequency, timing and impact on outcomes. EuroIntervention 2012; 8(1): 62-70.
[http://dx.doi.org/10.4244/EIJV8I1A11] [PMID: 22580250]
[85]
Tchetche D, Farah B, Misuraca L, et al. Cerebrovascular events post-transcatheter aortic valve replacement in a large cohort of patients: a FRANCE-2 registry substudy. JACC Cardiovasc Interv 2014; 7(10): 1138-45.
[http://dx.doi.org/10.1016/j.jcin.2014.04.018] [PMID: 25240554]
[86]
Dávila-Román VG, Murphy SF, Nickerson NJ, Kouchoukos NT, Schechtman KB, Barzilai B. Atherosclerosis of the ascending aorta is an independent predictor of long-term neurologic events and mortality. J Am Coll Cardiol 1999; 33(5): 1308-16.
[http://dx.doi.org/10.1016/S0735-1097(99)00034-0] [PMID: 10193732]
[87]
Zahn R, Schiele R, Gerckens U, et al. German Transcatheter Aortic Valve Interventions Registry Investigators. Transcatheter aortic valve implantation in patients with “porcelain” aorta (from a MulticenterReal World Registry). Am J Cardiol 2013; 111(4): 602-8.
[http://dx.doi.org/10.1016/j.amjcard.2012.11.004] [PMID: 23195040]
[88]
Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010; 55(11): 1080-90.
[http://dx.doi.org/10.1016/j.jacc.2009.12.014] [PMID: 20096533]
[89]
Pascual I, Avanzas P, Muñoz-García AJ, et al. Percutaneous implantation of the CoreValve® self-expanding valve prosthesis in patients with severe aortic stenosis and porcelain aorta: medium-term follow-up. Rev Española Cardiol (English Ed) 2013; 66: 775-81.
[90]
Carroll JD, Vemulapalli S, Dai D, et al. Procedural Experience for Transcatheter Aortic Valve Replacement and Relation to Outcomes: The STS/ACC TVT Registry. J Am Coll Cardiol 2017; 70(1): 29-41.
[http://dx.doi.org/10.1016/j.jacc.2017.04.056] [PMID: 28662805]
[91]
Auffret V, Regueiro A, Del Trigo M, et al. Predictors of Early Cerebrovascular Events in Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2016; 68(7): 673-84.
[http://dx.doi.org/10.1016/j.jacc.2016.05.065] [PMID: 27515325]
[92]
Rodés-Cabau J, Dumont E, Boone RH, et al. Cerebral embolism following transcatheter aortic valve implantation: comparison of transfemoral and transapical approaches. J Am Coll Cardiol 2011; 57(1): 18-28.
[http://dx.doi.org/10.1016/j.jacc.2010.07.036] [PMID: 21185496]
[93]
Wee IJY, Stonier T, Harrison M, Choong AMTL. Transcarotid transcatheter aortic valve implantation: A systematic review. J Cardiol 2018; 71(6): 525-33.
[http://dx.doi.org/10.1016/j.jjcc.2018.01.010] [PMID: 29499894]
[94]
Chamandi C, Mohammadi S, Dumont E, et al. Cerebral Embolism Following Transcarotid Transcatheter Aortic Valve Replacement. J Am Coll Cardiol 2018; 71(1): 101-2.
[http://dx.doi.org/10.1016/j.jacc.2017.10.075] [PMID: 29301616]
[95]
Nuis R-J, Van Mieghem NM, Schultz CJ, et al. Frequency and causes of stroke during or after transcatheter aortic valve implantation. Am J Cardiol 2012; 109(11): 1637-43.
[http://dx.doi.org/10.1016/j.amjcard.2012.01.389] [PMID: 22424581]
[96]
Amat-Santos IJ, Rodés-Cabau J, Urena M, et al. Incidence, predictive factors, and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. J Am Coll Cardiol 2012; 59(2): 178-88.
[http://dx.doi.org/10.1016/j.jacc.2011.09.061] [PMID: 22177537]
[97]
Dad T, Weiner DE. Stroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease Stages. Semin Nephrol 2015; 35(4): 311-22.
[http://dx.doi.org/10.1016/j.semnephrol.2015.06.003] [PMID: 26355250]
[98]
Holmes DR, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, et al. Thomas JD. 2012 ACCF/AATS/SCAI/ STS Expert consensus document on transcatheter aortic valve replacement. J Thorac Cardiovasc Surg 2012; 144: e29-84.
[http://dx.doi.org/10.1016/j.jtcvs.2012.03.001] [PMID: 22898522]
[99]
Dangas GD, Lefèvre T, Kupatt C, et al. BRAVO-3 Investigators. Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial. J Am Coll Cardiol 2015; 66(25): 2860-8.
[http://dx.doi.org/10.1016/j.jacc.2015.10.003] [PMID: 26477635]
[100]
Webb J, Rodés-Cabau J, Fremes S, et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol 2012; 28(5): 520-8.
[http://dx.doi.org/10.1016/j.cjca.2012.04.015] [PMID: 22703948]
[101]
Lip GYH, Collet JP, Haude M, et al. ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: A joint consensus document of the Europ. Europace 2019; 21(2): 192-3.
[http://dx.doi.org/10.1093/europace/euy174] [PMID: 30052888]
[102]
Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108(12): 1772-6.
[http://dx.doi.org/10.1016/j.amjcard.2011.07.049] [PMID: 21907949]
[103]
Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014; 174(3): 624-7.
[http://dx.doi.org/10.1016/j.ijcard.2014.04.170] [PMID: 24809922]
[104]
Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. Eur Heart J 2011; 32(2): 205-17.
[http://dx.doi.org/10.1093/eurheartj/ehq406] [PMID: 21216739]
[105]
Rodés-Cabau J, Masson JB, Welsh RC, et al. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. JACC Cardiovasc Interv 2017; 10(13): 1357-65.
[http://dx.doi.org/10.1016/j.jcin.2017.04.014] [PMID: 28527771]
[106]
Kappetein AP, Head SJ, Généreux P, et al. Valve Academic Research Consortium (VARC)-2. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). Eur J Cardiothorac Surg 2012; 42(5): S45-60.
[http://dx.doi.org/10.1093/ejcts/ezs533] [PMID: 23026738]
[107]
Maes F, Stabile E, Ussia GP, et al. Meta-Analysis Comparing Single Versus Dual Antiplatelet Therapy Following Transcatheter Aortic Valve Implantation. Am J Cardiol 2018; 122(2): 310-5.
[http://dx.doi.org/10.1016/j.amjcard.2018.04.006] [PMID: 29861051]
[108]
Vavuranakis M, Siasos G, Zografos T, et al. Dual or Single Antiplatelet Therapy After Transcatheter Aortic Valve Implantation? A Systematic Review and Meta-Analysis. Curr Pharm Des 2016; 22(29): 4596-603.
[http://dx.doi.org/10.2174/1381612822666160601110716] [PMID: 27262328]
[109]
Hioki H, Watanabe Y, Kozuma K, et al. OCEAN-TAVI investigators. Pre-procedural dual antiplatelet therapy in patients undergoing transcatheter aortic valve implantation increases risk of bleeding. Heart 2017; 103(5): 361-7.
[http://dx.doi.org/10.1136/heartjnl-2016-309735] [PMID: 27540180]
[110]
Poliacikova P, Cockburn J, de Belder A, Trivedi U, Hildick-Smith D. Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation - comparison of regimes. J Invasive Cardiol 2013; 25(10): 544-8.
[PMID: 24088430]
[111]
Didier R, Eltchaninoff H, Donzeau-Gouge P, et al. Five-Year Clinical Outcome and Valve Durability After Transcatheter Aortic Valve Replacement in High-Risk Patients. Circulation 2018; 138(23): 2597-607.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.036866] [PMID: 30571260]
[112]
Sherwood MW, Vemulapalli S, Harrison JK, et al. Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT Registry. Am Heart J 2018; 204: 9-16.
[http://dx.doi.org/10.1016/j.ahj.2018.06.006] [PMID: 30075326]
[113]
Czerwińska-Jelonkiewicz K, Zembala M, Dąbrowski M, et al. Can TAVI patients receive aspirin monotherapy as patients after surgical aortic bioprosthesis implantation? Data from the Polish Registry - POL-TAVI. Int J Cardiol 2017; 227: 305-11.
[http://dx.doi.org/10.1016/j.ijcard.2016.11.095] [PMID: 27843052]
[114]
Mangieri A, Jabbour RJ, Montalto C, et al. Single-Antiplatelet Therapy in Patients with Contraindication to Dual-Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. Am J Cardiol 2017; 119(7): 1088-93.
[http://dx.doi.org/10.1016/j.amjcard.2016.11.065] [PMID: 28237287]
[115]
Jimenez Diaz VA, Tello-Montoliu A, Moreno R, et al. Assessment of Platelet REACtivity After Transcatheter Aortic Valve Replacement: The REAC-TAVI Trial. JACC Cardiovasc Interv 2019; 12(1): 22-32.
[http://dx.doi.org/10.1016/j.jcin.2018.10.005] [PMID: 30621974]
[116]
Abdul-Jawad Altisent O, Durand E, Muñoz-García AJ, et al. Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv 2016; 9(16): 1706-17.
[http://dx.doi.org/10.1016/j.jcin.2016.06.025] [PMID: 27539691]
[117]
Vavuranakis M, Kalogeras K, Vrachatis D, et al. Antithrombotic therapy in patients undergoing TAVI with concurrent atrial fibrillation. One center experience. J Thromb Thrombolysis 2015; 40(2): 193-7.
[http://dx.doi.org/10.1007/s11239-015-1210-x] [PMID: 25863809]
[118]
Overtchouk P, Guedeney P, Rouanet S, et al. Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use: The FRANCE TAVI Registry. J Am Coll Cardiol 2019; 73(1): 13-21.
[http://dx.doi.org/10.1016/j.jacc.2018.08.1045] [PMID: 30153483]
[119]
Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17(10): 1467-507.
[http://dx.doi.org/10.1093/europace/euv309] [PMID: 26324838]
[120]
Geis NA, Kiriakou C, Chorianopoulos E, Uhlmann L, Katus HA, Bekeredjian R. NOAC monotherapy in patients with concomitant indications for oral anticoagulation undergoing transcatheter aortic valve implantation. Clin Res Cardiol 2018; 107(9): 799-806.
[http://dx.doi.org/10.1007/s00392-018-1247-x] [PMID: 29644411]
[121]
Carnicelli AP, De Caterina R, Halperin JL, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation 2017; 135(13): 1273-5.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.026714] [PMID: 28209729]
[122]
Windecker S, Tijssen J, Giustino G, et al. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. Am Heart J 2017; 184: 81-7.
[http://dx.doi.org/10.1016/j.ahj.2016.10.017] [PMID: 27892890]
[123]
TCTMD.com. GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm Available at https://www.tct md.com/news/galileo-trial-rivaroxaban-after-tavr-stopped-early-harm
[124]
Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI Available at:. https://clinicaltrials.gov/ct2/show/NCT01642134
[125]
Collet J-P, Berti S, Cequier A, et al. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. Am Heart J 2018; 200: 44-50.
[http://dx.doi.org/10.1016/j.ahj.2018.03.008] [PMID: 29898848]

Rights & Permissions Print Cite
Article Metrics
25
4
© 2024 Bentham Science Publishers | Privacy Policy